First results from the Genetic frontotemporal dementia (FTD) Initiative, and the advance of an HDAC inhibitor drug into Phase 2, made big splashes at the International Conference on Frontotemporal Dementias (ICFTD) conference held last month in Vancouver. Five hundred and ninety scientists from 30 countries met to exchange the latest clinical and scientific news on the diseases that make up FTLD. Multi-center cohort studies in Europe and North America reinforced the sense that there is a community spirit that may allow a common approach to how to develop therapies. Frontotemporal lobar degeneration can start in myriad ways—with social disinhibition, overeating, halting speech, or even odd misperceptions of pain or cold—but it always ends in dementia. Attendees said that the FTD field is poised for rapid progress.
Click here to read the full coverage by Alzforum’s Gabrielle Strobel and Jessica Shugart about the latest findings on FTLD proteins, clinical studies, and biomarkers!
To view commentaries, primary articles and linked stories, go to the original posting on Alzforum.org here.
Copyright 1996–2016 Biomedical Research Forum, LLC. All Rights Reserved.